Stephen Lillard
Pulmonary Disease · Troy, MONPI 1285625749
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by GSK at 26.6% of the total. Reporting peaked in 2019 at $1,095 and has fallen 98.3% since, to $18 in 2023. That places this record below the midpoint for pulmonary disease clinicians in MO, where the typical reported total is $1,482.
Across 113 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$503
- Boehringer Ingelheim$482
- Pulmonx Corporation$158
- Mylan Specialty L.p.$125
- Sunovion Pharmaceuticals Inc.$76
- Genentech USA, Inc.$58
- plus $491 from 22 others
What the payments were for
- Food & beverage$1,892100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 47 | $503 |
| Boehringer Ingelheim | 16 | $482 |
| Pulmonx Corporation | 3 | $158 |
| Mylan Specialty L.p. | 8 | $125 |
| Sunovion Pharmaceuticals Inc. | 5 | $76 |
| Genentech USA, Inc. | 4 | $58 |
| AstraZeneca | 4 | $52 |
| Jazz Pharmaceuticals Inc. | 1 | $42 |
| Novartis | 3 | $39 |
| United Therapeutics Corporation | 2 | $36 |
| Grifols USA, LLC | 2 | $31 |
| Johnson & Johnson | 2 | $28 |
| Resmed Corp | 1 | $24 |
| Advanced Respiratory, Inc | 1 | $21 |
| Insmed, Inc. | 1 | $19 |
| Circassia Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Sanofi | 1 | $18 |
| Masimo Corporation | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| OPKO Pharmaceuticals, LLC | 1 | $13 |
| Vifor Pharma, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Veran Medical Technologies, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,892 in reported general payments places this provider in the 50th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Troy
- Humam FarahHannibal$840K
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Munaf SiyamwalaIndependence$413K
- Edward CharbekSaint Louis$372K
- Adeel KhanWashington$316K
- Marin KollefSaint Louis$264K
- Praveen ChennaSaint Louis$255K
- Bobby ShahChesterfield$241K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.